As the first homologue of Bcl-2 found to be overexpressed in a number of hematological malignancies such as MM [316], and which conferred anti-apoptotic effects under normal conditions [317–320], Mcl1 expression was also reported to contribute to chemoresistance, thus highlighting its suitability to be targeted in combined therapeutic approaches. This evidence concerns the gene BCL2 and hematologic disorder.